Details of the Drug

General Information of Drug (ID: DMLB64C)

• Drug Name: EDP-1503

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]

• Drug Type: Live biotherapeutic product
• Cross-matching ID: TTD ID: DYU37E

References

• [1] ClinicalTrials.gov (NCT03595683) Pembrolizumab and EDP1503 in Advanced Melanoma. U.S. National Institutes of Health.